
ISSN: 2641-1652
*Corresponding author:
Dr Mark A Baxter, Department of Medical Oncology, Beatson West of Scotland Cancer Centre, 1053 Great Western Road, Glasgow, UKReceived: August 07, 2018; Published: August 10, 2018
DOI: 10.32474/CTGH.2018.01.000112
To view the Full Article Peer-reviewed Article PDF
Sorafenib is the current first line standard of care in patients with advanced hepatocellular carcinoma (HCC). Several other drugs are emerging as efficacious agents in this setting. This article will outline our current real-world experience with sorafenib in a Scottish population as well as discuss the evidence behind new potential therapies.
Keywords: Sorafenib; Hepatocellular carcinoma; HCC
Abbreviations: HCC: Hepatocellular Carcinoma; PS: Performance Status; OS: Overall Survival; TACE: Transarterial Chemoembolization; VEGF: Vascular Endothelial Growth Factor; PDGFR: Platelet Derived Growth Factor Receptor; FGFR: Fibroblast Growth Factor Receptor; WoS: West of Scotland
Abstract| Introduction| Results and Discussion| Conclusion| References|
Bio chemistry
University of Texas Medical Branch, USADepartment of Criminal Justice
Liberty University, USADepartment of Psychiatry
University of Kentucky, USADepartment of Medicine
Gally International Biomedical Research & Consulting LLC, USADepartment of Urbanisation and Agricultural
Montreal university, USAOral & Maxillofacial Pathology
New York University, USAGastroenterology and Hepatology
University of Alabama, UKDepartment of Medicine
Universities of Bradford, UKOncology
Circulogene Theranostics, EnglandRadiation Chemistry
National University of Mexico, USAAnalytical Chemistry
Wentworth Institute of Technology, USAMinimally Invasive Surgery
Mercer University school of Medicine, USAPediatric Dentistry
University of Athens , GreeceThe annual scholar awards from Lupine Publishers honor a selected number Read More...
The annual scholar awards from Lupine Publishers honor a selected number read more...